160 results
Search Results
Now showing 1 - 10 of 160
Item Metadata only Ischemic leg pain experiences, management strategies and outcomes in patients with peripheral arterial occlusion disease(Mahidol University. Mahidol University Library and Knowledge Center, 2007) Tidarat Panchoowong; Ketsarin UtriyaprasitItem Metadata only Efficacy and tolerability of galantamine in Thai alzheimer's patient with or without cerebrovascular disease and vascular dementia(Mahidol University. Mahidol University Library and Knowledge Center, 2004) Thanarat Suansanae; Chuthamanee SuthisisangPublication Metadata only Treatment outcomes of surgery, antifungal therapy and immunotherapy in ocular and vascular human pythiosis: A retrospective study of 18 patients(2014-01-01) Nitipong Permpalung; Navaporn Worasilchai; Rongpong Plongla; Sikarin Upala; Anawin Sanguankeo; Leilani Paitoonpong; Leonel Mendoza; Ariya Chindamporn; Chulalongkorn University; Columbia University, College of Physicians and Surgeons; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Mahidol University; Michigan State UniversityPythium insidiosum strains. Results: Eighteen patients were evaluated. Disease-free surgical margins were obtained in all surviving patients with vascular pythiosis (P1/40.08). Patients who underwent eye enucleation were significantly older than those who... did not (P,0.05). Patients with vascular or ocular pythiosis did not differ significantly in the median time from disease onset to first surgery or in the relationship between the type of P. insidiosum antigen and treatment outcomes. In vitroItem Metadata only Improved Survival in Vascular Pythiosis With Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial(2025-06-15) Torvorapanit P.; Worasilchai N.; Manothummetha K.; Srisurapanont K.; Thongkam A.; Langsiri N.; Leksuwankun S.; Meejun T.; Thanakitcharu J.; Lerttiendamrong B.; Susaengrat N.; Chuleerarux N.; Siriyakorn N.; Watcharasuwanseree S.; Suparatanachatpun P.; Chayangsu S.; Khemla S.; Kajeekul R.; Wattanasoontornsakul W.; Bansong R.; Sakulkonkij P.; Wongkamhla T.; Diewsurin J.; Laohasakprasit K.; Kongsakpaisal P.; Chayapum P.; Chindamporn A.; Plongla R.; Permpalung N.; Torvorapanit P.; Mahidol UniversityBackground Vascular pythiosis, caused by Pythium insidiosum, is a life-threatening disease with high mortality rate in patients with residual disease post-surgery. This study evaluated the effectiveness of a combination therapy of surgery....70). BDG levels decreased over time (odds ratio [OR] 0.82, 95% CI:. 77-.88 per week, P <. 001) but remained higher in the residual disease group (OR 4.29, 95% CI: 1.55-11.92) Conclusions The combination therapy of surgery, azithromycin, doxycyclinePublication Metadata only Outcomes and factors influencing prognosis in patients with vascular pythiosis(2016-08-01) Nuttawut Sermsathanasawadi; Banjerd Praditsuktavorn; Kiattisak Hongku; Chumpol Wongwanit; Khamin Chinsakchai; Chanean Ruangsetakit; Suteekhanit Hahtapornsawan; Pramook Mutirangura; Mahidol Universityinstitution with surgery, antifungal therapy, or immunotherapy. Methods We undertook a retrospective record review of patients with vascular pythiosis treated in Siriraj Hospital, Bangkok, Thailand, between January 2005 and January 2015. Patient...© 2016 Society for Vascular Surgery Objective Vascular pythiosis, caused by Pythium insidiosum, is associated with a high mortality rate. We reviewed the outcomes and established the factors predicting prognosis of patients treated in ourPublication Metadata only Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease(2005-12-01) A. Limsuwan; P. Pienvichit; P. Khowsathit; Mahidol UniversityWe present a report on children with severe pulmonary hypertension secondary to congenital heart disease who received 6 months of beraprost therapy. The children had an increase in intracardiac left-to-right shunt and a reduction of the pulmonary...-to-systemic vascular resistance ratio, whereas the pulmonary artery pressure was not significantly changed. © Springer Science+Business Media, Inc. 2005.Item Metadata only Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies(2022-01-01) Sumransub N.; Mahidol UniversityEndothelial dysfunction is characterized by altered vascular permeability and prothrombotic, pro-inflammatory phenotypes. Endothelial dysfunction results in end-organ damage and has been associated with diverse disease pathologies. Complications... observed after hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor-T cell (CAR-T) therapy for hematologic and neoplastic disorders share overlapping clinical manifestations and there is increasing evidence linking these complicationsPublication Metadata only Human pythiosis.(1996-12-01) M. Thianprasit; A. Chaiprasert; P. Imwidthaya; Mahidol Universityare not effective in the treatment of this infection. A saturated solution of KI gives a beneficial result only in the subcutaneous form. Surgical removal of the source of infection is the method of therapy of vascular and ophthalmic forms....Pythiosis is a cosmopolitan granulomatous disease caused by an aquatic fungus Pythium insidiosum which usually occurs in horses, cattle, dogs, cats or fishes. There have been 28 cases of human pythiosis published in the literature. Twenty threePublication Metadata only Chemotherapy for non-small-cell lung carcinoma: From a blanket approach to individual therapy(2011-04-22) Thanyanan Reungwetwattana; Matthew J. Eadens; Julian R. Molina; Mahidol University; Mayo Medical SchoolOnly one third of patients with non-small-cell lung carcinoma (NSCLC) present with early-stage disease that is amenable to potentially curative resection and adjuvant therapy. Unfortunately, even in stage I NSCLC, 5-year survival rates... surgery) or vice versa in early-stage NSCLC. Several emerging targeted therapy agents [e.g., inhibitors of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), or tyrosine kinase], and combination chemotherapy regimensPublication Metadata only Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial(2014-01-01) Masatoshi Kudo; Guohong Han; Richard S. Finn; Ronnie T.P. Poon; Jean Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won Young Tak; Xiaoping Yu; Joon Hyeok Lee; Shi Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B. Walters; Christine Dela Cruz; Valerie Poulart; Jian Hua Wang; Kindai University School of Medicine; The Fourth Military Medical University; David Geffen School of Medicine at UCLA; The University of Hong Kong; CHU Hopitaux de Bordeaux; West China Hospital of Sichuan University; Changhai Hospital; Guangdong General Hospital; Kyungpook National University Hospital; Hunan Provincial Tumor Hospital; SungKyunKwan University, School of Medicine; Chang Gung Memorial Hospital; First People's Hospital of Changzhou; Mahidol University; Zhejiang Cancer Hospital; Bristol-Myers Squibb; Bristol-Myers Squibb; Zhongshan Hospital Shanghai© 2014 by the American Association for the Study of Liver Diseases. Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor... of vascular endothelial growth factor and fibroblast growth factor signaling, may improve the effectiveness of TACE when given as an adjuvant to TACE. In this multinational, randomized, double-blind, placebo-controlled, phase III study, 870 patients with TACE